Mikart Revenue and Competitors

Atlanta, GA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Mikart's estimated annual revenue is currently $35.2M per year.(i)
  • Mikart's estimated revenue per employee is $201,000

Employee Data

  • Mikart has 175 Employees.(i)
  • Mikart grew their employee count by 9% last year.

Mikart's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP MarketingReveal Email/Phone
3
ControllerReveal Email/Phone
4
VP, Quality and RegulatoryReveal Email/Phone
5
Human Resources DirectorReveal Email/Phone
6
Director, Supply ChainReveal Email/Phone
7
Director Formulation DevelopmentReveal Email/Phone
8
Director, Quality OperationsReveal Email/Phone
9
Director Quality ControlReveal Email/Phone
10
Associate Director, Analytical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$24.5M1228%N/AN/A
#2
$10.7M53-17%N/AN/A
#3
$9.2M462%N/AN/A
#4
$24.1M1205%N/AN/A
#5
$7.2M36-20%N/AN/A
#6
$27.7M138-30%N/AN/A
#7
$39.8M19837%N/AN/A
#8
$0.5M525%$50MN/A
#9
$13.7M68-7%N/AN/A
#10
$10.3M5111%N/AN/A
Add Company

What Is Mikart?

Mikart offers contract pharmaceutical manufacturing services, specializing in oral capsule and tablet formulations. The company also provides specialty packaging and research support services. A recognized CDMO leader since 1975, Mikart has a wealth of expertise in pharmaceutical development, contract manufacturing and packaging services. Our manufacturing experience includes a broad range of drug compounds, including controlled drug substances.

keywords:N/A

N/A

Total Funding

175

Number of Employees

$35.2M

Revenue (est)

9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Mikart News

2022-04-19 - Dicyclomine Market Size, Scope And Forecast | Axcan ...

... Lannett, Mutual Pharmaceutical, Mylan, Pioneer Pharmaceuticals, Watson Laboratories, Hikma Pharmaceuticals, Alpharma and Mikart.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.9M1755%N/A
#2
$15M1751%N/A
#3
$40.4M175-23%N/A
#4
$48.1M175-3%N/A
#5
$42.6M176-7%N/A